Inflammatory Disease

AGENT TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION INDICATION
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10		 VEGFR2 Subcutaneous

Inflammatory Bowel Disease/Psoriasis
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10		 MAdCAM Subcutaneous

Inflammatory Bowel Disease
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10		 CD14 Subcutaneous

Sepsis
Diakine™- IL-4 dependent inflammation
IL-4 receptor pathway		 IL-4Ra Subcutaneous

Atopic Dermatitis/Asthma
Diakine™ Drug Conjugate
Autoimmune B cells

Systemic Lupus Erythematosus/Multiple Sclerosis/Myathenia Gravis
Diakine™ TCE Combination
Autoimmune B cells

Oncology

EXPERIMENTAL THERAPEUTIC TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PDOSE OPTIMIZATION INDICATION
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10		 EGFR Subcutaneous

Skin, Kidney, Lung, Bladder,

Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DKIFN-α 10 (EGFR)
IFN-α, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10		 VEGFR2 Subcutaneous

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7		 EGFR Intratumoral Injection

Various Solid Cancers
Diakine™- DK12IFN-α (EGFR)
aglycosylated IL-12, IFN-α		 EGFR Intratumoral Injection
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10		 CD19 Subcutaneous

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10		 CD20 Subcutaneous
Diakine™ Drug Conjugate
Growth Factor Dependent Cancers

Renal Cell Carcinoma (RCC)
Basal Cell Carcinoma (BCC)
Squanous Cell Carcinoma (skin) (SCC)
Cutaneous T cell Lymphoma (CTCL)
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-Small Cell Lung Cancer (NSCLC)
Head & Neck (H&N)
Colorectal Cancer (CRC) Prostate Cancer (PCa) Breast Cancer (TNBC) Ovarian Cancer (OC) Cervical Cancer (CC) Hematologic Malignancies
Diakine™ TCE Combination
All Cancers

INFLAMMATORY DISEASE
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10
TARGET: MAdCAM
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Inflammatory Bowel Disease
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Psoriasis/Rheumatoid Arthritis
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10
TARGET: CD14
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Sepsis
Diakine™- IL-4 dependent inflammation
IL-4 receptor pathway
TARGET: IL-4Ra
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Atopic Dermatitis/Athsma
Diakine™ Drug Conjugate
Autoimmune B cells
TARGET:
ADMINISTRATION:
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Systemic Lupus Erythematosus/Multiple Sclerosis/Myathenia Gravis
Diakine™ TCE Combination
Autoimmune B cells
TARGET:
ADMINISTRATION:
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Systemic Lupus Erythematosus/Multiple Sclerosis/Myathenia Gravis


ONCOLOGY
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DKalpha10 (EGFR)
IFN-α, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Various Solid Cancers
Diakine™- DK12alpha (EGFR)
aglycosylated IL-12, IFN-α
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Various Solid Cancers
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10
TARGET: CD19
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10
TARGET: CD20
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 PHASE 1 DOSE OP

Hematological Cancers

Inflammatory Disease

AGENT TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION INDICATION
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10		 VEGFR2 Subcutaneous

Inflammatory Bowel Disease/Psoriasis
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10		 MAdCAM Subcutaneous

Inflammatory Bowel Disease
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10		 CD14 Subcutaneous

Sepsis

Oncology

EXPERIMENTAL THERAPEUTIC TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 INDICATION
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10		 EGFR Subcutaneous

Skin, Kidney, Lung, Bladder,

Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DKIFN-α 10 (EGFR)
IFN-α, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10		 VEGFR2 Subcutaneous

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7		 EGFR Intratumoral Injection

Various Solid Cancers
Diakine™- DK12IFN-α (EGFR)
aglycosylated IL-12, IFN-α		 EGFR Intratumoral Injection
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10		 CD19 Subcutaneous

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10		 CD20 Subcutaneous

INFLAMMATORY DISEASE
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10
TARGET: MAdCAM
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Inflammatory Bowel Disease
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Psoriasis/Rheumatoid Arthritis
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10
TARGET: CD14
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Sepsis
Diakine™- IL-4 dependent inflammation
IL-4 receptor pathway
TARGET: IL-4Ra
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Atopic Dermatitis/Asthma
Diakine™ Drug Conjugate
Autoimmune B cells
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Systemic Lupus Erythematosus/Multiple Sclerosis/Myathenia Gravis
Diakine™ TCE Combination
Autoimmune B cells
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Systemic Lupus Erythematosus/Multiple Sclerosis/Myathenia Gravis


ONCOLOGY
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION/th>

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DKalpha10 (EGFR)
IFN-α, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Various Solid Cancers
Diakine™- DK12alpha (EGFR)
aglycosylated IL-12, IFN-α
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Various Solid Cancers
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10
TARGET: CD19
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10
TARGET: CD20
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Hematological Cancers
Diakine™ Drug Conjugate
Growth Factor Dependent Cancers
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Renal Cell Carcinoma (RCC)
Basal Cell Carcinoma (BCC)
Squanous Cell Carcinoma (skin) (SCC)
Cutaneous T cell Lymphoma (CTCL)
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-Small Cell Lung Cancer (NSCLC)
Head & Neck (H&N)
Colorectal Cancer (CRC) Prostate Cancer (PCa) Breast Cancer (TNBC) Ovarian Cancer (OC) Cervical Cancer (CC) Hematologic Malignancies
Diakine™ TCE Combination
All Cancers
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 DOSE OPTIMIZATION

Renal Cell Carcinoma (RCC)
Basal Cell Carcinoma (BCC)
Squanous Cell Carcinoma (skin) (SCC)
Cutaneous T cell Lymphoma (CTCL)
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-Small Cell Lung Cancer (NSCLC)
Head & Neck (H&N)
Colorectal Cancer (CRC) Prostate Cancer (PCa) Breast Cancer (TNBC) Ovarian Cancer (OC) Cervical Cancer (CC) Hematologic Malignancies